(Reuters) - BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use in Ebola, as it was awarded an additional $2.4 million in U.S. government funding. Birmingham, Alabama-based BioCryst's stock was up about 5 percent at $13.86 in trading before the bell on Friday. The biotechnology company received $4.1 million from the National Institute of Allergy and Infectious Diseases earlier this month to advance development of an intramuscular formulation of its drug, BCX4430. ...
via Health News Headlines - Yahoo News http://ift.tt/1n2AhjS
via Health News Headlines - Yahoo News http://ift.tt/1n2AhjS
No comments:
Post a Comment